Антигіпоксантна активність низькомолекулярної фракції кріогемолізату крові великої рогатої худоби на різних стадіях онтогенезу

Antihypoxant activity of low-molecular weight (below 5 kDa) fraction, obtained by ultrafiltration from cryohemolysate of umbilical/placental bovine and peripheral blood of 3-month-old calves and 4–5-year-old cows was studied. It was shown that injections of the fraction derived from bovine cord bl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Datum:2017
Hauptverfasser: Gulevsky, Oleksandr K., Schenyavsky, Ivan I.
Format: Artikel
Sprache:English
Veröffentlicht: Publishing House ‘Akademperiodyka’ of the National Academy of Sciences of Ukraine; Institute for Problems of Cryobiology and Cryomedicine 2017
Schlagworte:
Online Zugang:https://cryo.org.ua/journal/index.php/probl-cryobiol-cryomed/article/view/1277
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Problems of Cryobiology and Cryomedicine

Institution

Problems of Cryobiology and Cryomedicine
Beschreibung
Zusammenfassung:Antihypoxant activity of low-molecular weight (below 5 kDa) fraction, obtained by ultrafiltration from cryohemolysate of umbilical/placental bovine and peripheral blood of 3-month-old calves and 4–5-year-old cows was studied. It was shown that injections of the fraction derived from bovine cord blood and the one of 3-month-old calves unlike low molecular fraction of bovine blood significantly increased the survival time of mice in confined space and inhibited the accumulation of malon dialdehyde and lipid hydroperoxides in brain tissue at experimental confined space hypoxia. The effect after a preliminary 5-days course of injections of these drugs was the most pronounced. Thus, low molecular weight fraction below 5 kDa of blood at the early stages of ontogenesis had lower antihypoxant activity in animals with age. The obtained results testify to the fact that cryogenic technologies enable to use bovine cord blood as a raw material source for the production of pharmaceuticals with an antihypoxant action.Probl Cryobiol Cryomed 2017; 27(1): 41–50